ArticleJournal of endodontics2025
Viability of Dental Pulp Derived Stem Cells After Long-Term Cryopreservation.
Article in Journal of endodontics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phenotyping of Human Pulp Cells After Cryopreservation.Journal of cellular and molecular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionDental pulp-derived stem cells (DPSCs) have promise for use in regenerative therapies due to their regenerative and immunomodulatory potential. Following their isolation from dental pulp tissue, DPSCs can be cryopreserved and banked for future use, however, it remains unclear to what extent long-term storage affects their properties. This study evaluated the properties of DPSCs cryopreserved for up to 13 years.
methodsDPSCs from 12 patients cryopreserved for 5 (DPSC-5 YR), 10 (DPSC-10 YR), and 13 (DPSC-13 YR) years were analyzed for viability, immunophenotype (CD34, CD45, CD73, CD90, CD105), proliferation, and stemness. Additionally, senescence was evaluated through gene expression and senescence-associated β-galactosidase activity.
resultsAll cryopreserved DPSCs showed high expression of stem cell markers CD73, CD90, and CD105 (>90%) with low expression of hematopoietic markers CD34 and CD45 (<4%). Proliferative capacity and proliferation rate demonstrated no significant differences in population doubling time among groups, with values of 1.32 ± 0.41 for DPSC-5 YR, 1.36 ± 0.44 for DPSC-10 YR, and 1.38 ± 0.53 for DPSC-13 YR, all comparable to DPSCs cryopreserved for less than 1 year (1.37 ± 0.57). Osteogenic and adipogenic differentiation of DPSCs confirmed their ability to retain multipotency. Finally, senescence-associated β-galactosidase staining revealed an absence of senescent cells up to passage 6 and while stemness and senescence gene expression profiles varied, no significant differences were found in expression of these genes between DPSCs, regardless of numbers of years of cryopreservation.
conclusionsDPSCs can maintain viability, proliferative capacity, and stemness following long-term (up to 13 years) cryopreservation. These data support their long-term banking for clinical therapies aimed at tissue regeneration and immunomodulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.